What the FDA labels say about taking them together
Atazanavir and rivaroxaban
Atazanavir's FDA label of August 6, 2025 names rivaroxaban in its drug interactions section; the rivaroxaban labels PlainMeds reads (2) do not name atazanavir. The atazanavir label: “Coadministration of REYATAZ with ritonavir, a strong CYP3A4/P-gp inhibitor, and rivaroxaban is not recommended, as it may result in an increased risk of bleeding.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the rivaroxaban FDA label on DailyMed (effective September 10, 2026, Janssen Pharmaceuticals, Inc.).
What does the atazanavir label say about rivaroxaban?
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: rivaroxaban apixaban; Effect on Concentration of Atazanavir or Concomitant Drug: Atazanavir with ritonavir ↑ rivaroxaban Atazanavir ↑ rivaroxaban Atazanavir with ritonavir ↑ apixaban Atazanavir ↑ apixaban; Clinical Comment: Coadministration of atazanavir with ritonavir, a strong CYP3A4/P-gp inhibitor, and rivaroxaban is not recommended, as it may result in an increased risk of bleeding. Coadministration of atazanavir, a CYP3A4 inhibitor, and rivaroxaban may result in an increased risk of bleeding. Close monitoring is recommended when atazanavir is coadministered with rivaroxaban. …
Reyataz label (E.R. Squibb & Sons, L.L.C., December 5, 2024), drug interactionsConcomitant Drug Class/Specific Drugs: rivaroxaban; Effect on Concentration of Atazanavir or Concomitant Drug: REYATAZ with ritonavir ↑ rivaroxaban; Clinical Comment: Coadministration of REYATAZ with ritonavir, a strong CYP3A4/P-gp inhibitor, and rivaroxaban is not recommended, as it may result in an increased risk of bleeding.
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the rivaroxaban label say about atazanavir?
Rivaroxaban's label (effective September 10, 2026) and its 1 other brand-application label do not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Xarelto), Janssen Pharmaceuticals, Inc., effective September 10, 2026 (SPL set 10db92f9-2300-4a80-836b-673e1ae91610), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Rivaroxaban | |
|---|---|---|
| Labeled for | HIV | Atrial fibrillation, Heart attack and coronary artery disease, Blood clots (DVT and PE), Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.650 per tablet 2.5 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once